SBI Securities’s Kyverna Therapeutics KYTX Stock Holding History

SBI Securities’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.39K	Buy	204 +4	+2%	+$32	﹤0.01%	2738
2026 Q2	$1.78K	Buy	+200	New	+$1.78K	﹤0.01%	2592
2026 Q1	–	Sell	-22	Closed	-$207	–	4174
2025 Q4	$207	Sell	22 -115	-84%	-$854	﹤0.01%	3203
2025 Q3	$822	Sell	137 -23	-14%	-$92	﹤0.01%	2775
2025 Q2	$491	Buy	160 +20	+14%	+$49	﹤0.01%	2973
2025 Q1	$270	Hold	140	–	–	﹤0.01%	3110
2024 Q4	$524	Buy	+140	New	+$671	﹤0.01%	2875

Other funds holding KYTX

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return

Samalin Investment Counsel Chappaqua, New York $319M AUM 12.97% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

SBI Securities's KYTX Position: Q3 2026 in Review

SBI Securities increased its Kyverna Therapeutics (KYTX) stake by 2% in Q3 2026, buying an estimated $32 and bringing the position to 204 shares worth $1.39K. The position accounts for ﹤0.01% of the portfolio, ranked #2738.

SBI Securities first reported a position in KYTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.78K in Q2 2026. 10 funds tracked by Wall St. Rank hold KYTX as of Q3 2026.

SBI Securities held 204 shares of Kyverna Therapeutics worth $1.39K as of Q3 2026.
SBI Securities bought 4 Kyverna Therapeutics shares in Q3 2026, an estimated $32.
Kyverna Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #2738 holding.
SBI Securities first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Kyverna Therapeutics position peaked at $1.78K in Q2 2026.
10 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.